Peetz Christopher 4
4 · Arcutis Biotherapeutics, Inc. · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Arcutis (ARQT) Director Christopher Peetz Receives Award
What Happened
Christopher Peetz, a non-employee director of Arcutis Biotherapeutics (ARQT), received awards on July 15, 2026 totaling 38,811 shares (4,315 RSUs and two derivative awards of 21,486 and 13,010 underlying shares). All grants show a $0 acquisition price (standard for RSU/option awards); no cash changed hands. These are award/option grants (Form 4 code A) rather than purchases or sales.
Key Details
- Transaction date: July 15, 2026; filing date: July 17, 2026 (filed two business days after the transaction).
- Grants reported: 4,315 RSUs (F1); 21,486 derivative awards (F4); 13,010 derivative awards (F3). Total = 38,811 shares.
- Reported price: $0.00 (grants/awards). Total cash value at grant not reported on Form 4.
- Vesting highlights:
- 4,315 RSUs vest on the earlier of June 5, 2027 or immediately before the next annual meeting, subject to continued service (F1).
- 21,486 underlying shares vest 100% on the earlier of June 5, 2027 or immediately before the next annual meeting, subject to continued service (F4).
- 13,010 underlying shares vest in thirds annually beginning July 15, 2026, and are fully vested on the fourth anniversary of that date, subject to continued service (F3).
- Trust holdings: Footnote (F2) notes shares held by The Peetz Family Trust (he is a trustee and disclaims beneficial ownership except for pecuniary interest).
- Shares owned after transaction: not specified in the summary data provided in your request.
Context
These are standard director compensation awards (RSUs and option-style derivative grants) that convert to or permit purchase of common stock only if and when they vest/exercise under the schedules above. They are not sales or purchases in the open market and do not indicate an immediate change in market exposure (no immediate sale or cashless exercise reported). The filing appears timely (filed two days after the grants).
Insider Transaction Report
- Award
Common Stock
[F1]2026-07-15+4,315→ 4,315 total - Award
Stock Option (right to buy)
[F3]2026-07-15+21,486→ 21,486 totalExercise: $27.78Exp: 2036-07-15→ Common Stock (21,486 underlying) - Award
Stock Option (right to buy)
[F4]2026-07-15+13,010→ 13,010 totalExercise: $27.78Exp: 2036-07-15→ Common Stock (13,010 underlying)
- 187,500(indirect: By Trust)
Common Stock
[F2]
Footnotes (4)
- [F1]Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
- [F2]Shares held by The Peetz Family Trust dated February 15, 2017, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
- [F3]1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.
- [F4]The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.